Literature DB >> 8797586

Expression of cell cycle-regulated proteins in prostate cancer.

R D Mashal1, S Lester, C Corless, J P Richie, R Chandra, K J Propert, A Dutta.   

Abstract

Markers of cellular proliferation have proven to be useful prognostic markers in several tumor types. Recently, immunoreactivity for cyclins was found to provide an independent marker of tumor proliferation in breast cancer. In this study, we sought to determine the pattern of immunoreactivity for cyclins A, B, E, and Ki-67 in surgically resected prostate cancer and to determine their possible prognostic significance. Twenty-eight tumors of American Urological Association stages B and C were selected for study. Immunoreactivity for cyclins A and B was detected in most tumors and was present at significantly reduced levels as compared with breast cancer. Staining for cyclin E was present in four tumors and was present only in focal areas in two of the four. Such focal variation in expression of cell cycle regulators may reflect genetic instability in a tumor. Immunoreactivity for cyclins A and B was correlated with both Ki-67 index (the percentage of cells with Ki-67 immunoreactivity) and with each other. A Ki-67 index greater than 4.0 was associated with shorter time to prostate-specific antigen-detected relapse (P = 0.026). The fraction of cells staining for cyclins A and B divided by the fraction of cells staining for Ki-67 [(A+B)/K] was highly predictive of relapse, with values less than 0.50 associated with more rapid progression (P < 0.001). This latter result remained statistically significant after controlling for Gleason score by stratification. Our results suggest that immunoreactivity for markers of cellular proliferation may provide useful prognostic information in localized prostate cancer, and they need to be validated in a larger numbers of patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797586

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.

Authors:  Huarui Lu; Ping Liu; Yunqian Pan; Haojie Huang
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

2.  HIV-1 Tat regulates cyclin B1 by promoting both expression and degradation.

Authors:  Shi-Meng Zhang; Yi Sun; Rong Fan; Qin-Zhi Xu; Xiao-Dan Liu; Xiangming Zhang; Ya Wang; Ping-Kun Zhou
Journal:  FASEB J       Date:  2009-10-13       Impact factor: 5.191

3.  Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.

Authors:  Hina Mir; Neeraj Kapur; Rajesh Singh; Guru Sonpavde; James W Lillard; Shailesh Singh
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  Activation of cyclin E-dependent kinase activity in colorectal cancer.

Authors:  W R Cam; T Masaki; T Y Shiratori; N Kato; M Okamoto; Y Yamaji; K Igarashi; T Sano; M Omata
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

5.  Immunohistochemical Expression of Cyclin B1 in Epithelial Hyperplasia, Dysplasia and Oral Squamous Cell Carcinomas - A Comparative Study.

Authors:  Kochli Channappa Niranjan; Amsavardani Tayaar; G S Kumar; Rekha Krishnapillai; Kaveri Hallikeri; Santosh Hunasgi
Journal:  J Clin Diagn Res       Date:  2016-09-01

6.  Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor.

Authors:  Jae Uk Shin; Chang Hoon Lee; Kyu Taek Lee; Jong Kyun Lee; Kwang Hyuck Lee; Kwang Min Kim; Kyoung-Mee Kim; Sang-Mo Park; Jong Chul Rhee
Journal:  Tumour Biol       Date:  2012-06-16

7.  Cyclin B1 expression and p53 status in squamous cell carcinomas of the head and neck.

Authors:  Thomas K Hoffmann; Sokratis Trellakis; Kornelia Okulicz; Patrick Schuler; Jens Greve; Judith Arnolds; Christoph Bergmann; Murat Bas; Stephan Lang; Götz Lehnerdt; Sven Brandau; Stefan Mattheis; Kathrin Scheckenbach; Oliviera J Finn; Theresa L Whiteside; Enikö Sonkoly
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

8.  G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).

Authors:  Kaoru Nemoto
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

9.  The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2016-07-22

10.  Expression of geminin as a marker of cell proliferation in normal tissues and malignancies.

Authors:  James A Wohlschlegel; Jeffery L Kutok; Andrew P Weng; Anindya Dutta
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.